Debut transaction more than three times oversubscribed

The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/

Dr. Almuth Steinkühler, Chief Financial Officer Merz Group

The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions.

With the successful placement, Merz has further diversified its funding base by complementing its existing syndicated financing arrangements with an additional source of long-term capital. The transaction also broadens the company’s investor base and enhances the diversification and resilience of its overall financing structure.

The transaction was arranged by BNP Paribas and DZ BANK. Hogan Lovells Cadwalader acted as legal counsel to Merz Pharma Group.

Dr. Almuth Steinkühler, Chief Financial Officer Merz Group:

“The strong demand for our inaugural Schuldschein loan reflects investors’ confidence in Merz Group’s financial strength, long-term growth prospects, and strategic direction. By successfully accessing the Schuldschein market, we have further diversified our funding sources, strengthened our financial flexibility and created a solid foundation to support the group’s future organic and inorganic growth.”

Karsten Kabas, Senior Vice President Group Treasury, Insurance & Financial Investments Merz Group:

“We are particularly pleased that our debut transaction not only generated exceptionally strong demand but also enabled us to achieve a credit spread of less than 100 basis points on the five-year benchmark tranche. In addition, we successfully attracted investors for a ten-year tranche, underscoring the market’s confidence in Merz as a long-term borrower.”

About Merz Group

Founded in 1908, Merz Group is a family-owned company headquartered in Frankfurt, Germany. The group comprises seven companies, including its three largest businesses: Merz Aesthetics, one of the world's leading providers of aesthetic medicine products and treatments; Merz Therapeutics, a pharmaceutical company focused on neurological disorders; and Merz Lifecare, a provider of over-the-counter healthcare products with well-known brands such as tetesept, Merz Spezial, SOS, and Zirkulin. With these brands, Merz Lifecare is one of the market leaders in the German-speaking region.

Merz Group employs more than 5,500 people worldwide and generated approximately €2.5 billion in revenue in the last fiscal year.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260716926041/en/

Media Contact:
Jesko Giessen
Head of Group Communications
Merz Group
office: +49 69 1503 2581 | mobile: + 49 1511 6480 378
merz.com | Eckenheimer Landstraße 100, 60318 Frankfurt am Main, GERMANY

Images

Tags

More Like This

Valmet strengthens its financial position with EUR 375 million long-term Schuldschein loan

Merz Enters Asset Purchase Agreement With a US-Based Biotech Company

Galderma Successfully Placed an Inaugural EUR 500 Million Single Tranche Eurobond and New Dual Tranche CHF 435 Million CHF Bonds

Galderma Completes Successful Placement of CHF 175 Million Bond

Galderma Successfully Issued an Inaugural CHF 500 Million Bond

FIS SUCCESSFULLY COMPLETES €770 MILLION BOND ISSUANCE

Merz Therapeutics Hosts Over 300 International Healthcare Professionals at its First Global “Merz Expert Connect Summit 2023”

dsm-firmenich issues €800 million long-term bond